Clinical Trial Update: AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating AMG 436 as monotherapy and in combination for patients with MSI-H/dMMR solid tumors, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Locally Advanced Solid Tumors with Microsatellite Instability-high or Mismatch Repair Deficiency

Drugs mentioned

• AMG 436

Snippet

Sponsor: Amgen | Conditions: Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) | Phase 1 | Status: RECRUITING